Trial of Curcumin in Cutaneous T-cell Lymphoma Patients

Key facts

Sponsor

M.D. Anderson Cancer Center

Principal Investigator

Madeleine Duvic, MD

UT MD Anderson Cancer Center

Intervention

Curcumin (Turmeric)(drug)

Eligibility

All sexes

Timeline

2012

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Aggressive primary cutaneous T-cell lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT05544968
  Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
  Medical College of Wisconsin
• RECRUITINGPHASE1NCT07055477
  A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
  National Cancer Institute (NCI)
• RECRUITINGPHASE1NCT07047885
  Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
  H. Lee Moffitt Cancer Center and Research Institute
• RECRUITINGNANCT06860880
  Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
  UNC Lineberger Comprehensive Cancer Center
• RECRUITINGPHASE1, PHASE2NCT07022964
  CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
  Beijing GoBroad Hospital
• RECRUITINGNCT07132567
  Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
  Kyowa Kirin Co., Ltd.
• RECRUITINGPHASE1, PHASE2NCT06925464
  CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
  Beijing GoBroad Hospital
• RECRUITINGPHASE1NCT06914037
  A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
  Tianjin Medical University Cancer Institute and Hospital

See all trials for Aggressive primary cutaneous T-cell lymphoma →